202822-84-2

Basic information

• Product Name: 1,3,4-Oxadiazol-2(3H)-one, 3-[[5-chloro-4-(ethylmethylamino)-2-methoxyphenyl]methyl]-5-[4-(trifluoro methyl)phenyl]-
• CAS NO: 202822-84-2
• Molecular Formula: C20H19ClF3N3O3
• Molecular Weight: 441.837
• Mol File: 202822-84-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1,3,4-Oxadiazol-2(3H)-one, 3-[[5-chloro-4-(ethylmethylamino)-2-methoxyphenyl]methyl]-5-[4-(trifluoro methyl)phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3,4-Oxadiazol-2(3H)-one, 3-[[5-chloro-4-(ethylmethylamino)-2-methoxyphenyl]methyl]-5-[4-(trifluoro methyl)phenyl]-(202822-84-2)
• EPA Substance Registry System: 1,3,4-Oxadiazol-2(3H)-one, 3-[[5-chloro-4-(ethylmethylamino)-2-methoxyphenyl]methyl]-5-[4-(trifluoro methyl)phenyl]-(202822-84-2)

Safety Data

• Hazardous Substances Data: 202822-84-2(Hazardous Substances Data)

Usage

Chemical structure

A complex molecule with a 1,3,4-oxadiazole ring and various substituents.

Substituents

Ethylmethylamino, methoxyphenyl, and trifluoromethyl groups.

Potential applications

Pharmaceutical industry, specifically in the development of new drugs for various health conditions.

Structural features

May contribute to specific biological activities or interactions within the body.

Further study

Interesting target for potential drug development due to its unique structure.

Industrial applications

The unique structure may also hold potential for use in other industrial applications.

Upstream product

• 202822-77-3 4-(N-ethyl-N-methylamino)-5-chloro-2-methoxybenzenemethanol 
• 202823-22-1 5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-(3H)-one 
• 4093-31-6 methyl 2-methoxy 4-acetamido 5-chloro benzoate 
• 455-24-3 4-trifluoromethylbenzoic acid 
• 339-59-3 4-(trifluoromethyl)benzoic acid hydrazide 
• 202822-76-2 4-(N-acetyl-N-methylamino)-5-chloro-2-methoxybenzoic acid methyl ester 

Relevant articles and documents

3-[(5-Chloro-2-hydroxyphenyl)methyl]-5-[4-(trifluoromethyl)phenyl]-1,3, 4-oxadiazol-2(3H)-one, BMS-191011: Opener of large-conductance Ca 2+-activated potassium (maxi-K) channels, identification, solubility, and SAR

Compound 8a (BMS-191011), an opener of the cloned large-conductance, Ca2+-activated potassium (maxi-K) channel, demonstrated efficacy in in vivo stroke models, which led to its nomination as a candidate for clinical evaluation. Its maxi-K channel opening properties were consistent with its structural topology, being derived by combining elements from other known maxi-K openers. However, 8a suffered from poor aqueous solubility, which complicated elucidation of SAR during in vitro evaluation. The activity of 8a in in vivo stroke models and studies directed toward improving its solubility are reported herein. Enhanced solubility was achieved by appending heterocycles to the 8a scaffold, and a notable observation was made that inclusion of a simple amino group (anilines 8k and 8l) yielded excellent in vitro maxi-K ion channel opening activity and enhanced brain-to-plasma partitioning compared to the appended heterocycles.